Compare Stocks

Date Range: 

 Merck & Co., Inc.Novo Nordisk A/SAbbott LaboratoriesAbbVieEli Lilly and
SymbolNYSE:MRKNYSE:NVONYSE:ABTNYSE:ABBVNYSE:LLY
Price Information
Current Price$75.74$97.70$121.74$116.01$265.81
50-Day Moving Average$76.63$85.02$115.27$115.19$227.61
52-Week Low$71.71$63.22$98.67$79.11$129.21
52-Week High$87.80$93.34$128.54$119.15$259.37
MarketRank™
Overall Score2.81.52.93.02.7
Analysis Score3.40.02.42.42.5
Community Score4.54.04.84.94.8
Dividend Score2.52.54.25.02.5
Ownership Score2.50.02.51.72.5
Earnings & Valuation Score1.31.30.61.31.3
Analyst Ratings
Consensus RecommendationBuyHoldBuyBuyBuy
Consensus Price Target$93.26N/A$124.67$121.24$238.21
% Upside from Price Target23.13% upsideN/A2.40% upside4.51% upside-10.38% downside
Trade Information
Market Cap$191.78 billion$230.06 billion$216.31 billion$204.90 billion$254.92 billion
Beta0.410.420.660.820.26
Average Volume8,543,681905,3894,679,7325,921,7812,412,721
Sales & Book Value
Annual Revenue$47.99 billion$19.45 billion$34.61 billion$45.80 billion$24.54 billion
Price / Sales4.0011.836.254.4710.39
Cashflow$7.35 per share$3.27 per share$5.61 per share$13.81 per share$9.64 per share
Price / Cash10.3029.8521.698.4027.56
Book Value$10.04 per share$4.12 per share$18.62 per share$7.42 per share$6.09 per share
Price / Book7.5423.716.5415.6343.65
Profitability
Net Income$7.07 billion$6.46 billion$4.50 billion$4.62 billion$6.19 billion
EPS$5.94$2.76$3.65$10.56$7.93
Trailing P/E Ratio34.5833.9234.2931.2739.73
Forward P/E Ratio12.1029.0826.128.2631.57
P/E Growth2.233.382.301.731.97
Net Margins11.48%33.77%15.85%12.40%23.91%
Return on Equity (ROE)53.80%71.90%27.00%150.27%132.28%
Return on Assets (ROA)16.15%30.84%12.39%14.04%16.36%
Dividend
Annual Payout$2.60$1.33$1.80$5.20$3.40
Dividend Yield3.43%1.36%1.48%4.48%1.28%
Three-Year Dividend Growth31.22%13.65%35.85%84.37%42.31%
Payout Ratio43.77%48.19%49.32%49.24%42.88%
Years of Consecutive Dividend Growth1 Years1 Years49 Years49 Years1 Years
Debt
Debt-to-Equity Ratio0.89%0.05%0.52%5.40%2.28%
Current Ratio1.02%0.85%1.75%0.83%1.42%
Quick Ratio0.78%0.59%1.32%0.73%1.10%
Ownership Information
Institutional Ownership Percentage71.71%5.56%72.99%65.98%81.57%
Insider Ownership Percentage0.32%0.07%1.50%0.09%0.13%
Miscellaneous
Employees74,00045,323109,00047,00035,000
Shares Outstanding2.53 billion2.35 billion1.78 billion1.77 billion959.03 million
Next Earnings Date10/26/2021 (Estimated)8/5/2021 (Confirmed)10/20/2021 (Estimated)10/29/2021 (Estimated)10/26/2021 (Estimated)
OptionableOptionableOptionableOptionableOptionableOptionable
SourceHeadline
Eli Lilly and (NYSE:LLY) PT Raised to $300.00Eli Lilly and (NYSE:LLY) PT Raised to $300.00
marketbeat.com - August 4 at 11:15 AM
Live: Jim Cramer on Under Armour, BP, DuPont, Eli Lilly, Clorox, COVIDLive: Jim Cramer on Under Armour, BP, DuPont, Eli Lilly, Clorox, COVID
msn.com - August 4 at 8:21 AM
Eli Lilly and (NYSE:LLY) Announces  Earnings ResultsEli Lilly and (NYSE:LLY) Announces Earnings Results
americanbankingnews.com - August 3 at 8:28 PM
Eli Lilly and Company (LLY) Q2 2021 Earnings Call TranscriptEli Lilly and Company (LLY) Q2 2021 Earnings Call Transcript
finance.yahoo.com - August 3 at 7:43 PM
Eli Lilly and (NYSE:LLY) Updates FY21 Earnings GuidanceEli Lilly and (NYSE:LLY) Updates FY21 Earnings Guidance
americanbankingnews.com - August 3 at 5:16 PM
‘Tug of war’ as investors digest mixed market messages‘Tug of war’ as investors digest mixed market messages
financialpost.com - August 3 at 4:59 PM
Eli Lilly and (NYSE:LLY) Hits New 52-Week High at $256.38Eli Lilly and (NYSE:LLY) Hits New 52-Week High at $256.38
americanbankingnews.com - August 3 at 4:40 PM
Eli Lilly bets on Alzheimers disease drug data as it chases BiogenEli Lilly bets on Alzheimer's disease drug data as it chases Biogen
msn.com - August 3 at 2:42 PM
S&P 500 Climbs as Energy, Industrials ShineS&P 500 Climbs as Energy, Industrials Shine
finance.yahoo.com - August 3 at 2:42 PM
Eli Lilly Earnings Missed Expectations. Why the Stock Is Soaring.Eli Lilly Earnings Missed Expectations. Why the Stock Is Soaring.
finance.yahoo.com - August 3 at 2:42 PM
Eli Lilly Stock Hits A Record High Despite Mixed Quarter As Alzheimers Enthusiasm GrowsEli Lilly Stock Hits A Record High Despite Mixed Quarter As Alzheimer's Enthusiasm Grows
finance.yahoo.com - August 3 at 2:42 PM
Eli Lilly (LLY) Q2 Earnings Miss, Sales Beat, Stock DownEli Lilly (LLY) Q2 Earnings Miss, Sales Beat, Stock Down
finance.yahoo.com - August 3 at 2:42 PM
Eli Lilly and (NYSE:LLY) Updates FY 2021 Earnings GuidanceEli Lilly and (NYSE:LLY) Updates FY 2021 Earnings Guidance
americanbankingnews.com - August 3 at 1:50 PM
Eli Lilly CEO on the companys Q2 earnings and core business performanceEli Lilly CEO on the company's Q2 earnings and core business performance
msn.com - August 3 at 9:42 AM
MIT spinout raises $30M, scores J&J, Eli Lilly partnershipsMIT spinout raises $30M, scores J&J, Eli Lilly partnerships
bizjournals.com - August 3 at 9:42 AM
Drugmaker Eli Lilly profit hit by weak demand for pandemic drugsDrugmaker Eli Lilly profit hit by weak demand for pandemic drugs
news.yahoo.com - August 3 at 9:42 AM
CNBCs full interview with Eli Lilly CEO David RicksCNBC's full interview with Eli Lilly CEO David Ricks
cnbc.com - August 3 at 9:42 AM
Eli Lilly And Co. Q2 adjusted earnings of $1.87 per shareEli Lilly And Co. Q2 adjusted earnings of $1.87 per share
nasdaq.com - August 3 at 9:42 AM
Drugmaker Eli Lilly reports 2% drop in quarterly profitDrugmaker Eli Lilly reports 2% drop in quarterly profit
reuters.com - August 3 at 9:42 AM
Drugmaker Eli Lilly Profit Slips on Weak Demand for COVID-19 TherapiesDrugmaker Eli Lilly Profit Slips on Weak Demand for COVID-19 Therapies
money.usnews.com - August 3 at 9:42 AM
Eli Lilly Stock Slides on Earnings Miss, Outlook Change; Trulicity Sales ImpressEli Lilly Stock Slides on Earnings Miss, Outlook Change; Trulicity Sales Impress
msn.com - August 3 at 9:42 AM
Lilly Q2 Profit Down; Cuts FY21 EPS, Margin View; Backs Adj. Earnings Forecast Lilly Q2 Profit Down; Cuts FY21 EPS, Margin View; Backs Adj. Earnings Forecast
rttnews.com - August 3 at 8:13 AM
Lilly’s COVID-19 drug reduces death risk in patients on mechanical ventilationLilly’s COVID-19 drug reduces death risk in patients on mechanical ventilation
financialpost.com - August 3 at 6:47 AM
Lilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial GuidanceLilly Delivers Strong Second-Quarter 2021 Financial Results, Updates 2021 Financial Guidance
prnewswire.com - August 3 at 6:47 AM
Eli Lilly Near Record High Ahead of Earnings; Target Price $300 in Best CaseEli Lilly Near Record High Ahead of Earnings; Target Price $300 in Best Case
fxempire.com - August 3 at 4:42 AM
Lilly coronavirus treatment offers powerful defense against virus complicationsLilly coronavirus treatment offers powerful defense against virus complications
wishtv.com - August 2 at 10:24 PM
Eli Lilly and (NYSE:LLY) Coverage Initiated by Analysts at TruistEli Lilly and (NYSE:LLY) Coverage Initiated by Analysts at Truist
marketbeat.com - July 29 at 12:15 AM
Eli Lilly and (NYSE:LLY) Receives "Buy" Rating from MizuhoEli Lilly and (NYSE:LLY) Receives "Buy" Rating from Mizuho
marketbeat.com - July 7 at 12:06 PM
DateCompanyBrokerageAction
8/4/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
8/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
8/4/2021Eli Lilly andMizuho
Boost Price Target
8/3/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
8/2/2021AbbVieSVB Leerink
Boost Price Target
8/2/2021AbbVieMizuho
Boost Price Target
8/2/2021AbbVieBarclays
Boost Price Target
7/30/2021Merck & Co., Inc.SVB Leerink
Boost Price Target
7/27/2021Merck & Co., Inc.Truist Securities
Initiated Coverage
7/27/2021Merck & Co., Inc.Truist
Initiated Coverage
7/27/2021AbbVieTruist Securities
Initiated Coverage
7/27/2021AbbVieTruist
Initiated Coverage
7/27/2021Eli Lilly andTruist
Initiated Coverage
7/23/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
7/23/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
7/23/2021Abbott LaboratoriesRaymond James
Boost Price Target
7/20/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
7/19/2021Novo Nordisk A/SBarclays
Reiterated Rating
7/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Reiterated Rating
7/12/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
7/7/2021Eli Lilly andMizuho
Reiterated Rating
7/6/2021Eli Lilly andBarclays
Boost Price Target
7/2/2021AbbVieDaiwa Capital Markets
Initiated Coverage
7/2/2021Eli Lilly andTruist Securities
Boost Price Target
7/2/2021Eli Lilly andTruist
Boost Price Target
6/24/2021Eli Lilly andCantor Fitzgerald
Boost Price Target
6/24/2021Eli Lilly andCowen
Boost Price Target
6/15/2021Eli Lilly andJPMorgan Chase & Co.
Boost Price Target
6/14/2021Eli Lilly andThe Goldman Sachs Group
Boost Price Target
6/9/2021Merck & Co., Inc.JPMorgan Chase & Co.
Lower Price Target
6/8/2021Eli Lilly andTruist Securities
Reiterated Rating
6/8/2021Eli Lilly andTruist Financial
Reiterated Rating
6/7/2021Merck & Co., Inc.Truist Securities
Lower Price Target
6/3/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
6/2/2021Abbott LaboratoriesBTIG Research
Lower Price Target
6/2/2021Abbott LaboratoriesCredit Suisse Group
Lower Price Target
6/2/2021Abbott LaboratoriesBarclays
Lower Price Target
6/2/2021Abbott LaboratoriesWells Fargo & Company
Lower Price Target
6/2/2021Abbott LaboratoriesRaymond James
Lower Price Target
6/2/2021Abbott LaboratoriesMorgan Stanley
Lower Price Target
6/2/2021Abbott LaboratoriesCitigroup
Reiterated Rating
5/24/2021Abbott LaboratoriesBarclays
Initiated Coverage
5/20/2021Merck & Co., Inc.Argus
Reiterated Rating
5/3/2021AbbVieBMO Capital Markets
Boost Price Target
5/3/2021AbbVieMizuho
Boost Price Target
4/30/2021Merck & Co., Inc.SVB Leerink
Lower Price Target
4/30/2021AbbViePiper Sandler
Boost Price Target
4/28/2021Eli Lilly andMorgan Stanley
Lower Price Target
4/28/2021Eli Lilly andMizuho
Lower Price Target
4/28/2021Eli Lilly andBarclays
Lower Price Target
4/21/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
4/20/2021Abbott LaboratoriesWilliam Blair
Reiterated Rating
4/15/2021Abbott LaboratoriesAtlantic Securities
Initiated Coverage
4/7/2021AbbVieRoyal Bank of Canada
Initiated Coverage
3/30/2021AbbVieSVB Leerink
Boost Price Target
3/15/2021Eli Lilly andTruist Securities
Boost Price Target
3/11/2021Abbott LaboratoriesRaymond James
Boost Price Target
2/12/2021Eli Lilly andCowen
Boost Price Target
2/11/2021Novo Nordisk A/SUBS Group
Reiterated Rating
2/5/2021Merck & Co., Inc.Cantor Fitzgerald
Reiterated Rating
2/4/2021Novo Nordisk A/SBarclays
Reiterated Rating
2/4/2021AbbVieSVB Leerink
Boost Price Target
2/4/2021AbbVieRoyal Bank of Canada
Boost Price Target
2/4/2021AbbVieMizuho
Boost Price Target
2/4/2021Eli Lilly andMorgan Stanley
Boost Price Target
2/1/2021Eli Lilly andTruist
Boost Price Target
2/1/2021Eli Lilly andMizuho
Boost Price Target
2/1/2021Eli Lilly andBarclays
Boost Price Target
1/28/2021Abbott LaboratoriesWells Fargo & Company
Boost Price Target
1/28/2021Abbott LaboratoriesCowen
Boost Price Target
1/28/2021Abbott LaboratoriesCredit Suisse Group
Boost Price Target
1/28/2021Abbott LaboratoriesMorgan Stanley
Boost Price Target
1/28/2021Abbott LaboratoriesSVB Leerink
Boost Price Target
1/28/2021Abbott LaboratoriesRaymond James
Boost Price Target
1/28/2021Abbott LaboratoriesBTIG Research
Upgrade
1/28/2021AbbVieMorgan Stanley
Lower Price Target
1/22/2021Eli Lilly andBank of America
Boost Price Target
1/20/2021Novo Nordisk A/SCredit Suisse Group
Downgrade
1/19/2021Eli Lilly andMizuho
Upgrade
1/15/2021Novo Nordisk A/SDeutsche Bank Aktiengesellschaft
Initiated Coverage
12/16/2020AbbVieSVB Leerink
Boost Price Target
12/15/2020Abbott LaboratoriesMorgan Stanley
Boost Price Target
12/15/2020AbbVieMizuho
Boost Price Target
12/6/2020Merck & Co., Inc.Mizuho
Reiterated Rating
11/30/2020AbbVieMorgan Stanley
Boost Price Target
11/18/2020AbbVieBMO Capital Markets
Initiated Coverage
11/12/2020Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
11/10/2020Merck & Co., Inc.Sanford C. Bernstein
Reiterated Rating
11/10/2020AbbVieSanford C. Bernstein
Initiated Coverage
11/6/2020Novo Nordisk A/SMorgan Stanley
Downgrade
11/3/2020Novo Nordisk A/SSociete Generale
Reiterated Rating
11/2/2020AbbVieSVB Leerink
Lower Price Target
10/29/2020Merck & Co., Inc.SVB Leerink
Boost Price Target
10/23/2020Merck & Co., Inc.Truist
Initiated Coverage
10/23/2020AbbVieTruist
Initiated Coverage
10/20/2020AbbVieThe Goldman Sachs Group
Downgrade
10/16/2020Merck & Co., Inc.JPMorgan Chase & Co.
Boost Price Target
10/16/2020AbbVieJPMorgan Chase & Co.
Boost Price Target
10/15/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
9/29/2020Merck & Co., Inc.Berenberg Bank
Initiated Coverage
9/29/2020Novo Nordisk A/SBerenberg Bank
Initiated Coverage
9/29/2020AbbVieBerenberg Bank
Initiated Coverage
9/22/2020Merck & Co., Inc.Mizuho
Reiterated Rating
8/25/2020Merck & Co., Inc.SVB Leerink
Boost Price Target
8/18/2020Novo Nordisk A/SUBS Group
Reiterated Rating
8/4/2020Merck & Co., Inc.Royal Bank of Canada
Reiterated Rating
8/3/2020Merck & Co., Inc.The Goldman Sachs Group
Upgrade
8/3/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
7/31/2020Merck & Co., Inc.Mizuho
Reiterated Rating
7/6/2020Novo Nordisk A/SBank of America
Downgrade
6/23/2020Merck & Co., Inc.Mizuho
Reiterated Rating
6/23/2020Merck & Co., Inc.Morgan Stanley
Reiterated Rating
6/12/2020Merck & Co., Inc.Wolfe Research
Downgrade
5/18/2020Novo Nordisk A/SMorgan Stanley
Reiterated Rating
5/13/2020Novo Nordisk A/SJPMorgan Chase & Co.
Reiterated Rating
5/11/2020Novo Nordisk A/SUBS Group
Downgrade
5/7/2020Novo Nordisk A/SSociete Generale
Reiterated Rating
5/4/2020Merck & Co., Inc.Credit Suisse Group
Reiterated Rating
5/4/2020Novo Nordisk A/SCowen
Initiated Coverage
4/29/2020Merck & Co., Inc.Guggenheim
Lower Price Target
3/23/2020Novo Nordisk A/SUBS Group
Upgrade
3/16/2020Novo Nordisk A/SBank of America
Upgrade
1/3/2020Novo Nordisk A/SGuggenheim
Downgrade
11/27/2019Novo Nordisk A/SBarclays
Upgrade
11/22/2019Novo Nordisk A/SPareto Securities
Downgrade
(Data available from 8/4/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.